Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

New research from The George Institute for Global Health at the University of Oxford has found significant gender bias in research authorship relating to COVID-19, which means that women’s views are not equally shaping the response to the pandemic.

Women are under-represented as authors of research papers in many scientific areas, particularly in the most senior positions of first and last author, and this research published today in BMJ Global Health finds the trend persisting in publications on COVID-19.

The research team analysed publications on COVID-19 since the onset of the pandemic in January 2020 to identify the representation of women in any authorship position, and as first or last author. Overall, women represented just over one third (34%) of all authors. Only 29% of the 1,235 papers assessed by first author were women, while this was even lower for last author at just 26% (of 1,216 papers).

“Our findings on the major gender gap in research authorship on COVID-19, and in the most senior positions in particular, mirrors the under-representation of women in other areas of science research; a trend that has persisted for years”, said Dr Ana-Catarina Pinho-Gomes of The George Institute UK, who led the analysis.

Read the full story on the University of Oxford website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.